Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Raghav on a Phase 2 Study of ABBV-400 Plus Fluorouracil, Folinic Acid, and Bevacizumab in Pretreated Metastatic CRC
January 26th 2025, 12:36am
Gastrointestinal Cancers Symposium (ASCO GI)
Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.
Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer
January 26th 2025, 12:35am
Gastrointestinal Cancers Symposium (ASCO GI)
Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.
Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC
January 25th 2025, 11:55pm
Gastrointestinal Cancers Symposium (ASCO GI)
Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.
Nivolumab Plus Ipilimumab Prolongs PFS vs Nivolumab Alone in MSI-H/dMMR mCRC
January 25th 2025, 11:50pm
Gastrointestinal Cancers Symposium (ASCO GI)
Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.
Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
January 25th 2025, 10:01pm
Gastrointestinal Cancers Symposium (ASCO GI)
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.
Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC
January 25th 2025, 9:51pm
Gastrointestinal Cancers Symposium (ASCO GI)
Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.
Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC
January 25th 2025, 8:45pm
Gastrointestinal Cancers Symposium (ASCO GI)
Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer
January 25th 2025, 7:40pm
Gastrointestinal Cancers Symposium (ASCO GI)
Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.
Single-Cycle Neoadjuvant Pembrolizumab Is Efficacious, Safe in dMMR Colon Cancer
January 25th 2025, 7:37pm
Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.
Trifluridine/Tipiracil Demonstrates DFS Benefit Over Placebo in Resected Stage IV CRC
January 25th 2025, 6:50pm
Gastrointestinal Cancers Symposium (ASCO GI)
Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.
Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer
January 25th 2025, 6:33pm
The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.
Dose Reductions of Liposomal Irinotecan, Oxaliplatin Are Not Associated With Worsened OS in Metastatic PDAC
January 25th 2025, 5:50pm
Gastrointestinal Cancers Symposium (ASCO GI)
NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.
First-Line FOLFIRINOX Fails to Improve OS vs First-Line NALIRIFOX in Metastatic PDAC
January 25th 2025, 5:40pm
Gastrointestinal Cancers Symposium (ASCO GI)
The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.
Aspirin Is Associated With Reduced Recurrence Risk in PI3K+ CRC
January 25th 2025, 3:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.
ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer
January 25th 2025, 3:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.
Addition of CRT to Chemotherapy Does Not Improve RFS in Resected Gallbladder Cancer
January 25th 2025, 12:34am
Gastrointestinal Cancers Symposium (ASCO GI)
Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.
Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer
January 25th 2025, 12:24am
Gastrointestinal Cancers Symposium (ASCO GI)
Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.
Pelareorep Plus mFOLFIRINOX ± Atezolizumab Shows Acceptable Safety in Metastatic PDAC
January 24th 2025, 11:12pm
Gastrointestinal Cancers Symposium (ASCO GI)
Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.
NIPS Boosts Overall Survival Over PS in Gastric Cancer With Peritoneal Metastasis
January 24th 2025, 10:10pm
Gastrointestinal Cancers Symposium (ASCO GI)
Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.
Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer
January 24th 2025, 9:29pm
Gastrointestinal Cancers Symposium (ASCO GI)
Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.